Sort by
Refine Your Search
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The UCL Cancer Institute is the hub for basic biological and translational cancer research at University College London, one of the world's leading universities. The Institute draws
-
collaborators. This post is available from 31st March 2026 or as soon as possible thereafter for approximately 36 months in the first instance due to funding restrictions thereafter. Salary will be UCL Grade 7
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
About us UCL is a diverse global community of world-class academics, students, industry links, external partners, and alumni. Our powerful collective of individuals and institutions work together to
-
About us The “Next-Gen Biopharma Manufacturing 5.0” Prosperity Partnership is a 5-year collaborative programme between UCL Biochemical Engineering and AstraZeneca, jointly funded by EPSRC and
-
The research fellow will work in the research groups of Helen Hailes in the Department of Chemistry, UCL, and Sanjib Bhakta at Birkbeck, University of London. The project will be focused